L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson's disease : emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
RATIONALE: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. The pathogenesis of PD includes oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter dysregulation. L-theanine is found in green tea and has antioxidant, anti-inflammatory, and neuroprotective effects with a high blood brain barrier permeability.
OBJECTIVE: The objective of this study was to investigate the possible neuroprotective effect of L-theanine in lipopolysaccharide (LPS) induced motor deficits and striatal neurotoxicity in a rat model of PD.
METHODS: LPS was infused at a dose of 5 μg/5 μl PBS stereotaxically into SNpc of rats. Treatment with L-theanine (50 and 100 mg/kg; po) and Sinemet (36 mg/kg; po) was given from day 7 to 21 in of LPS injected rat. On a weekly basis all behavioral parameters were assessed, and animals were sacrificed on day 22. The striatum tissue of brain was isolated for biochemicals (Nitrite, GSH, catalase, SOD, mitochondrial complexes I and IV), neuroinflammatory markers, and neurotransmitters (serotonin, dopamine, norepinephrine, GABA, and glutamate) estimations.
RESULTS: Results revealed that L-theanine dose-dependently and significantly reversed motor deficits, assessed through locomotor and rotarod activity. Moreover, L-theanine attenuated biochemical markers, reduced oxidative stress, and neurotransmitters dysbalance in the brain. L-theanine treatment at 100 mg/kg; po substantially reduced these pathogenic events by increasing mitochondrial activity, restoring neurotransmitter levels, and inhibiting neuroinflammation.
CONCLUSIONS: These data suggest that the positive effects of L-theanine on motor coordination may be mediated by the suppression of NF-κB induced by LPS. Therefore, L-theanine would have a new therapeutic potential for PD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:240 |
|---|---|
| Enthalten in: |
Psychopharmacology - 240(2023), 7 vom: 19. Juli, Seite 1493-1508 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Shivam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3KX376GY7L |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 19.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00213-023-06382-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356943291 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356943291 | ||
| 003 | DE-627 | ||
| 005 | 20231226071527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00213-023-06382-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356943291 | ||
| 035 | |a (NLM)37191688 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Shivam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson's disease |b emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 19.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a RATIONALE: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. The pathogenesis of PD includes oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter dysregulation. L-theanine is found in green tea and has antioxidant, anti-inflammatory, and neuroprotective effects with a high blood brain barrier permeability | ||
| 520 | |a OBJECTIVE: The objective of this study was to investigate the possible neuroprotective effect of L-theanine in lipopolysaccharide (LPS) induced motor deficits and striatal neurotoxicity in a rat model of PD | ||
| 520 | |a METHODS: LPS was infused at a dose of 5 μg/5 μl PBS stereotaxically into SNpc of rats. Treatment with L-theanine (50 and 100 mg/kg; po) and Sinemet (36 mg/kg; po) was given from day 7 to 21 in of LPS injected rat. On a weekly basis all behavioral parameters were assessed, and animals were sacrificed on day 22. The striatum tissue of brain was isolated for biochemicals (Nitrite, GSH, catalase, SOD, mitochondrial complexes I and IV), neuroinflammatory markers, and neurotransmitters (serotonin, dopamine, norepinephrine, GABA, and glutamate) estimations | ||
| 520 | |a RESULTS: Results revealed that L-theanine dose-dependently and significantly reversed motor deficits, assessed through locomotor and rotarod activity. Moreover, L-theanine attenuated biochemical markers, reduced oxidative stress, and neurotransmitters dysbalance in the brain. L-theanine treatment at 100 mg/kg; po substantially reduced these pathogenic events by increasing mitochondrial activity, restoring neurotransmitter levels, and inhibiting neuroinflammation | ||
| 520 | |a CONCLUSIONS: These data suggest that the positive effects of L-theanine on motor coordination may be mediated by the suppression of NF-κB induced by LPS. Therefore, L-theanine would have a new therapeutic potential for PD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a L-theanine | |
| 650 | 4 | |a Lipopolysaccharide | |
| 650 | 4 | |a NF-κB | |
| 650 | 4 | |a Neurotransmitters | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 7 | |a theanine |2 NLM | |
| 650 | 7 | |a 8021PR16QO |2 NLM | |
| 650 | 7 | |a Lipopolysaccharides |2 NLM | |
| 650 | 7 | |a Neurotransmitter Agents |2 NLM | |
| 650 | 7 | |a Glutamic Acid |2 NLM | |
| 650 | 7 | |a 3KX376GY7L |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 700 | 1 | |a Awasthi, Anupam |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Khadga |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Shamsher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychopharmacology |d 1977 |g 240(2023), 7 vom: 19. Juli, Seite 1493-1508 |w (DE-627)NLM00009434X |x 1432-2072 |7 nnns |
| 773 | 1 | 8 | |g volume:240 |g year:2023 |g number:7 |g day:19 |g month:07 |g pages:1493-1508 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00213-023-06382-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 240 |j 2023 |e 7 |b 19 |c 07 |h 1493-1508 | ||